UK's NICE rec­om­mends against cov­er­age for As­traZeneca and Dai­ichi's breast can­cer drug En­her­tu over cost-ef­fec­tive­ness

The UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence (NICE) said Tues­day that it won’t rec­om­mend cov­er­age of As­traZeneca and Dai­ichi Sankyo’s can­cer drug En­her­tu …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER